Miriam J C Calaguas

Publications (2)10.17 Total impact

• Article: Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.

  Shingo Kato, Tatsuya Ohno, Kullathorn Thephamongkhol, Yaowalak Chansilpa, Yang Yuxing, C R Beena Devi, Anita Z Bustam, Miriam J C Calaguas, Rey H de los Reyes, Chul-Koo Cho, To Anh Dung, Nana Supriana, Hideyuki Mizuno, Takashi Nakano, Hirohiko Tsujii
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the toxicity and efficacy of concurrent chemoradiotherapy using weekly cisplatin for patients with locally advanced cervical cancer in East and Southeast Asia, a multi-institutional Phase II clinical study was conducted among eight Asian countries. Between April 2003 and March 2006, 120 patients (60 with bulky Stage IIB and 60 with Stage IIIB) with previously untreated squamous cell carcinoma of the cervix were enrolled in the present study. Radiotherapy consisted of pelvic external beam radiotherapy (total dose, 50 Gy) and either high-dose-rate or low-dose-rate intracavitary brachytherapy according to institutional practice. The planned Point A dose was 24-28 Gy in four fractions for high-dose-rate-intracavitary brachytherapy and 40-45 Gy in one to two fractions for low-dose-rate-intracavitary brachytherapy. Five cycles of weekly cisplatin (40 mg/m(2)) were administered during the radiotherapy course. All patients were eligible for the study. The median follow-up was 27.3 months. Of the 120 patients, 100 (83%) received four or five cycles of chemotherapy. Acute Grade 3 leukopenia was observed in 21% of the patients, and Grade 3 gastrointestinal toxicity was observed in 6%. No patient failed to complete the radiotherapy course because of toxicity. The 2-year local control and overall survival rate for all patients was 87.1% and 79.6%, respectively. The 2-year major late rectal and bladder complication rate was 2.5% and 0%, respectively. The results have suggested that concurrent chemoradiotherapy using weekly cisplatin is feasible and effective for patients with locally advanced cervical cancer in East and Southeast Asia.
  International journal of radiation oncology, biology, physics 10/2009; 77(3):751-7. · 4.59 Impact Factor
• Article: A regional cooperative clinical study of radiotherapy for cervical cancer in east and south-east Asian countries.

  Takashi Nakano, Shingo Kato, Jianping Cao, Juying Zhou, Raden Susworo, Nana Supriana, Shinichiro Sato, Tatsuya Ohno, Hisao Suto, Yuzuru Nakamura, Chul-Koo Cho, Fuad B Ismail, Miriam J C Calaguas, Rey H de Los Reyes, Yaowalak Chansilpa, Kullathom Thephamongkhol, Nguyen Ba Duc, To Anh Dung, Hirohiko Tsujii
  [show abstract] [hide abstract]
  ABSTRACT: Radiotherapy differed widely in east and south-east Asia because of technical, cultural, and socio-economic differences. With the purpose of standardizing radiotherapy for cervical cancer in the region, an international clinical study was conducted. Eleven institutions in eight Asian countries participated in the study. Between 1996 and 1998, 210 patients with stage IIIB cervical cancer were enrolled. Patients were treated with a combination of external beam radiotherapy (total dose, 50Gy) and either high-dose-rate (HDR) or low-dose-rate (LDR) intracavitary brachytherapy (ICBT) according to the institutional practice. The planned point A dose was 20-28Gy/4 fractions for HDR-ICBT and 30-40Gy/1-2 fractions for LDR-ICBT. Hundred patients were treated with HDR-ICBT and 110 were treated with LDR-ICBT. The ICBT doses actually delivered to point A ranged widely: 12-32Gy in the HDR group and 26-52.7Gy in the LDR group. The 5-year follow-up rate among the countries differed greatly, from 29% to 100%. The 5-year major complication rates were 6% in the HDR group and 10% in the LDR group. The 5-year overall survival rates were 51.1% in the HDR group and 57.5% in the LDR group. Although there were several problems with treatment compliance and patients' follow-up, the study suggests that the protocols provided favorable outcomes with acceptable rates of late complications in the treatment of advanced cervical cancer in east and south-east Asia.
  Radiotherapy and Oncology 10/2007; 84(3):314-9. · 5.58 Impact Factor